Novo Nordisk to invest $1.05b in Monte Claros facility in Brazil
HQ Team April 10, 2025: Novo Nordisk will invest 6.4 billion reais ($1.05 billion) in Brazil’s Monte Claros to expand its production of.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team April 10, 2025: Novo Nordisk will invest 6.4 billion reais ($1.05 billion) in Brazil’s Monte Claros to expand its production of.
HQ Team March 21, 2025: A study from China adds to mounting evidence that semaglutide—a medication widely used for type 2 diabetes (Ozempic).
Eli Lilly and Company cut the prices of its weight-loss drug Zepbound, available in single-dose vials, in a bid to end compounding companies from.
HQ Team January 21, 2024: The popular diabetes drugs, glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic, have gained immense popularity for their.
HQ Team November 8, 2024: The rise of weight loss medications such as Ozempic (semaglutide) and Wegovy has sparked significant interest and usage.
Denmark’s Novo Nordisk got the backing of the European Medicines Agency for its Wegovy drug to reduce heart failure in obese people.
HQ Team August 22, 2024: A new study based on data from the World Health Organization’s records on adverse drug reactions found that.
HQ Team July 31, 2024: A new research published in the Annals of Internal Medicine reveals that semaglutide is effective in helping people quit.
Overdose of weight-loss drugs and dosing errors by patients and healthcare providers have led to adverse events, including hospitalisation, the USFDA warned.
The European Medicines Agency has backed Novo Nordisk’s Wegovy to expand the weight-loss drug’s application to lower heart risks and strokes in non-diabetic.